Gefitinib sensitization of cisplatin-resistant wild-type EGFR non-small cell lung cancer cells

PURPOSE: The usual first-line strategy of wild-type EGFR (wtEGFR) non-small cell lung cancer (NSCLC) remains cisplatin-based chemotherapy. However, cisplatin often loses effectiveness because most tumors acquire drug resistance over time. As EGFR is the most important pro-survival/proliferation sign...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:J Cancer Res Clin Oncol
Main Authors: Li, Amin, Cao, Weiya, Liu, Xueke, Zhang, Yinci, Ma, Yongfang, Xu, Ruyue, Zhang, Rongbo, Liu, Xinkuang, Zhou, Shuping, Wang, Ruikai, Liu, Jiachang, Tang, Xiaolong
Format: Artigo
Jezik:Inglês
Izdano: Springer Berlin Heidelberg 2020
Teme:
Original Article – Cancer Research
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7185832/
https://ncbi.nlm.nih.gov/pubmed/32342201
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00432-020-03228-4
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki